Ra Pharmctl Inc (RARX) Expected to Post Earnings of -$0.74 Per Share
Wall Street analysts forecast that Ra Pharmctl Inc (NASDAQ:RARX) will post earnings of ($0.74) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Ra Pharmctl’s earnings. Ra Pharmctl posted earnings per share of ($14.22) during the same quarter last year, which indicates a positive year-over-year growth rate of 94.8%. The business is expected to report its next quarterly earnings report on Tuesday, December 5th.
On average, analysts expect that Ra Pharmctl will report full year earnings of ($2.54) per share for the current fiscal year, with EPS estimates ranging from ($2.63) to ($2.45). For the next financial year, analysts anticipate that the firm will post earnings of ($3.15) per share, with EPS estimates ranging from ($3.55) to ($2.75). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Ra Pharmctl.
Ra Pharmctl (NASDAQ:RARX) last released its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06).
Several brokerages have recently issued reports on RARX. Zacks Investment Research raised Ra Pharmctl from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. Royal Bank Of Canada began coverage on Ra Pharmctl in a research note on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target on the stock. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Ra Pharmctl in a research note on Friday, July 14th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Ra Pharmctl currently has a consensus rating of “Buy” and an average price target of $24.00.
Ra Pharmctl (NASDAQ:RARX) traded down 4.25% on Thursday, reaching $15.33. The company had a trading volume of 18,578 shares. Ra Pharmctl has a 12 month low of $12.05 and a 12 month high of $27.84. The company’s market capitalization is $346.60 million. The company’s 50 day moving average price is $14.83 and its 200-day moving average price is $14.83.
Large investors have recently added to or reduced their stakes in the business. American International Group Inc. acquired a new position in Ra Pharmctl in the first quarter valued at about $102,000. TIAA CREF Investment Management LLC lifted its stake in Ra Pharmctl by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares during the period. Wells Fargo & Company MN lifted its stake in Ra Pharmctl by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares during the period. Alliancebernstein L.P. acquired a new position in Ra Pharmctl in the second quarter valued at about $195,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Ra Pharmctl by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after buying an additional 2,543 shares during the period. 66.26% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/19/ra-pharmctl-inc-rarx-expected-to-post-earnings-of-0-74-per-share-2.html.
About Ra Pharmctl
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.